Lunai Bioworks Files For Non Timely 10-K With U.S. SEC; Anticipates Reporting A Net Loss For The Fiscal Year Ended June 30, 2026 Of ~$3.2M

The Company anticipates reporting a net loss for the fiscal year ended June 30, 2026 of approximately $3.2 million, compared to a net loss of approximately $178.0 million for the fiscal year ended June 30, 2025. The anticipated decrease in net loss is principally attributable to the absence in fiscal 2026 of the approximately $170.4 million goodwill impairment charge recorded in fiscal 2025, the approximately $10.4 million decrease in general and administrative expenses following the Company’s restructuring, the approximately $12.0 million gain recognized upon the deconsolidation of GEDi Cube B.V. following its bankruptcy, partially offset by the approximately $7.4 million loss on extinguishment of debt recognized in connection with the Company’s fiscal 2026 debt restructuring and debt exchange transactions, the approximately $0.832 million impairment of long-lived assets in connection with changes to operating leases and a less favorable year-over-year change of approximately $11.1 million in the fair value of contingent consideration.